The apo C-II gene from a patient with apo C-1I deficiency has been sequenced after amplification by the polymerase chain reaction. A substitution of an adenosine for a guanosine at position 3002 in exon 3 of the patient's gene was identified by sequence analysis. This mutation leads to the introduction of a premature termination codon (TAA) at a position corresponding to amino acid 37 of mature apo C-II and to the formation of a new Rsa I restriction enzyme site not present in the normal apo C-II gene. Amplification of DNA from family members by the polymerase chain reaction and digestion with Rsa I established that the patient is a true homozygote for the mutation. Analysis of the patient's plasma by two-dimensional gel electrophoresis and immunoblotting detected an apo C-II that exhibited abnormal electrophoretic mobility. We propose that the C to A substitution in the apo C-Ipdova gene is the primary genetic defect that leads to premature termination and the synthesis of a truncated 36 amino acid apo C-II that is unable to activate lipoprotein lipase.
Introduction
Apo C-II is a 79 amino acid protein that plays a central role in triglyceride metabolism as a cofactor for the enzyme lipoprotein lipase (1) . In the presence of apo C-II lipoprotein lipase hydrolyzes triglycerides present in chylomicrons and VLDL to monoglycerides, diglycerides, and FFA. The importance of apo C-II as a physiological activator of lipoprotein lipase was established by the identification of patients with a deficiency of apo C-II, a rare disease inherited as an autosomal recessive trait (2) (3) (4) (5) (6) (7) (8) . Patients with apo C-II deficiency develop type I hyperlipoproteinemia with fasting chylomicronemia and hypertriglyceridemia. Clinical features include eruptive xanthomas, lipemia retinalis, hepatosplenomegaly, and an increased risk of pancreatitis. The diagnosis of apo C-II deficiency is established by finding a virtual absence of apo C-1I in plasma associated with reduced postheparin lipoprotein lipase activity that is corrected by the addition of normal apo C-II-containing plasma. In two patients evidence of a circulating inhibitor of lipoprotein lipase activity has been described (9, 10) .
We have recently described the genetic defect that leads to deficiency of apo C-II in the probands from the Hamburg and Receivedfor publication 5 June 1989 and in revisedform 17 July 1989. Nijmegen kindreds (1 1, 12) . Sequence analysis of the apo CIIHamburg gene revealed a single base substitution that leads to abnormal splicing of the apo C-IIHamburg mRNA. Reduced levels of normal apo C-Il could be detected in the plasma of the proband from the Hamburg kindred plasma by two-dimensional gel electrophoresis and immunoblotting. In the apo C-IlNjimegen DNA, a deletion of a guanosine results in the introduction of a premature termination mutation and the synthesis of a truncated 17 amino acid peptide instead of the 79 residues present in normal apo C-II. However, this peptide was not detected in the patient's plasma by RIA or immunoblot analysis. The defects in apo C-IIToronto (13) and apo C-Ilst. Michael (14) have been studied at the protein level. Both of these mutant apo can be easily detected in plasma, are nonfunctional, and have an altered amino acid sequence at the carboxyl-terminal end.
In the present manuscript we investigate the genetic defect in the apo C-Il gene of the proband from the Padova kindred. A novel substitution of a cytosine for an adenosine at position 3002 of the third exon of the apo ClIpadova gene has been identified by sequence analysis. This mutation introduces a premature termination codon in the apo C-IIpadova gene that leads to the synthesis of a truncated apo C-II peptide. We propose that this base substitution ultimately leads to the deficiency of apo C-II observed in this kindred.
Methods
Experimental subjects. The two affected individuals from the Padova kindred have been previously described (15).
DNA and RNA preparation. RNA was isolated from frozen liver using the guanidine thiocyanate method (16) NORMAL scribed (23) . The gels were stained by the silver stain method (24) . The proteins separated by two-dimensional gel electrophoresis were transferred to nitrocellulose paper at 80 V for I h. Apo C-II was detected by using a monospecific rabbit apo C-Il antisera as the first antibody and visualized by indirect immunoperoxidase assay on nitrocellulose paper according to the manufacturer's instructions (Bio-Rad Laboratories, Richmond, CA).
Results
Sequence analysis of the four exons, all splice junctions, and the 5' and 3' untranslated regions of the apo C-IIpadova gene revealed a single base substitution at position 3002 (data not shown). Fig. 1 illustrates the genomic organization of the apo C-II gene and the position of the C to A mutation in exon 3 identified during the sequence analysis of the apo C-IIPadova gene. This substitution leads to the introduction of a premature termination codon (TAA) at a position corresponding to amino acid 37 of the normal apo C-II and, ultimately, to the synthesis of a truncated 36 amino acid apo C-II peptide. Fig. 2 contains autoradiography of sequencing gels ofthe DNA from normal and apo C-II-deficient subjects in the region of the mutation. The C to A substitution in base 3002 ofthe patient's apo C-II gene is indicated by the arrow.
Computer analysis (Fristensky-Cornell DNA Sequencing Analysis Program) of the apo C-IIpadova gene sequence containing the C to A mutation revealed the loss of an Rsa I restriction enzyme site present at position 3000 of the normal apo C-II gene (19) . Amplifications of the apo C-II genes from normal and apo C-II-deficient subjects were performed by the PCR as illustrated in Fig. 3 . Digestion of amplified normal DNA with Rsa I should result in the formation of two fragments of 385 and 132 bp. Digestion of DNA amplified from the patient, however, should lead to the formation of a single fragment of 517 bp (Fig. 3) as the Rsa I restriction enzyme site was destroyed by the mutation. Northern blot analysis of total liver RNA from normal subjects and the apo C-II-deficient patient performed by hybridization with an apo C-II cDNA probe is shown in Fig. 6 . As expected for a premature termination mutation, the patient's apo C-II mRNA was of normal size when compared with the normal control apo C-1I message. Despite the reduced levels of apo C-II present in plasma, the amount of apo C-Il mRNA and protein in the liver of the apo C-IIpadova proband was previously shown to be normal by slot blot hybridization and immunohistochemistry (25) .
Analyses of apo C-Il in the plasma of the normal and apo C-II-deficient subjects were performed by two-dimensional gel electrophoresis and immunoblotting (Fig. 7) . As in previous studies (15), normal apo C-II could not be detected in the proband's plasma but an abnormal C-IIpaddva apo was found. The apparent molecular weight of apo C-IIpaddva was found to be closer to 8,000 D than to the 4,500 D expected for the 36 amino acid peptide predicted by the sequencing studies. To investigate this discrepancy, a synthetic peptide consisting of the first 36 amino terminal residues of apo C-11 was synthesized and analyzed by two-dimensional gel electrophoresis (Fig. 7) . Results indicated that the synthetic as well as the native apo C-TI peptides comigrated at the same position in the gel and thus have the same pI and apparent molecular weight, which was larger than that expected for a 36 residue protein. This confirms that the apo C-IIpadova protein detected in the patient's plasma by immunoblot studies was the truncated apo C-Il protein that exhibited abnormal electrophoretic behavior on two-dimensional gel analysis.
Discussion
In the present study we analyzed the genetic defect that leads to the deficiency of apo C-IT in the proband from the Padova kindred. Sequence analysis of the patient's gene revealed a substitution of a C for an A in exon III that leads to the introduction of a premature termination codon at a position corresponding to amino acid 37 ofnormal apo C-II and thus to the synthesis of a truncated protein. Since this truncated apo C-Il peptide lacks the carboxyl-terminal end that contains the activating domain for apo C-Il (26), it will not activate lipoprotein lipase and thus leads to deficiency of apo C-IT activity in this patient.
Analysis of the apo C-II gene from immediate family members of the Padova kindred by the PCR, followed by restriction enzyme digestion with Rsa I, established that the two affected individuals were true homozygotes for the mutation. This finding suggested that despite the absence of a family history of consanguinity there is inbreeding in this kindred. The same has been true of other apo C-Il-deficient families previously described (1 1, 12 Northern blot hybridization analysis indicated that the apo C-II mRNA in the patient's liver is of normal size, which is consistent with the premature termination mutation identified by our sequencing analysis. Interestingly, despite markedly reduced plasma apo C-II levels, normal amounts of both apo 28s -18s
AApoC-1 mRNA C-IT mRNA and protein were detected intrahepatically (26) , which suggests that the mutant apo is either abnormally secreted from hepatocytes or rapidly catabolized in plasma. This is in contrast to the apo C-IT-deficient proband from Nijmegen (12) , who also had a nonsense mutation in exon III (base 2943) and very low intrahepatic levels of apo C-II mRNA. Most in vivo nonsense mutations described to date lead to decreased mRNA accumulation by mechanisms that are not clearly understood. These may involve altered intranuclear stability, abnormal nuclear to cytoplasmic transport of the mRNA, or decreased stability of the intracellular mRNA (27, 28) . However, two recent studies indicate that a nonsense mutation will not necessarily result in a decreased level of steady-state mRNA (29, 30) . Thus, normal mRNA levels have been identified for the LDL receptor and the ,B-globin chain in patients that have nonsense mutations of these genes. Both of these mutations, as well as the premature termination mutation in the apo C-Ilpadova DNA are located closer to the 3' end of the respective genes than other previously described nonsense mutations in those genes. This observation may be similar to what has been described in prokaryotes, where the effect of nonsense mutations on mRNA accumulation is polar, with mutations located near the 5' end ofthe gene resulting in lower mRNA accumulation than those closer to the 3' end (31) . It may be that critical nuclear events needed for mRNA accumulation do not occur with more proximal mutations.
Analysis of plasma from the apo C-IT-deficient patient by two-dimensional electrophoresis and immunoblotting revealed a protein that exhibited a larger apparent molecular weight than that expected for a 36 residue protein. The 36 amino acid synthetic peptide comigrated on two-dimensional gel electrophoresis with the native apo C-IIpadov,a protein, confirming that the apo C-IIpadova protein migrated at a larger apparent molecular weight of -8,000 D. The reason for this behavior is unclear, but may involve dimerization of the peptide through hydrophobic interactions that are not disrupted by detergents.
In conclusion, the genetic abnormality that leads to deficiency ofapo C-II in the Padova kindred has been identified. A single base substitution (C to A) in the third exon of the apo CIIPadova gene leads to the introduction of a premature termination mutation and the synthesis of a truncated apo C-Il 
